Have you ever wondered if there’s a way to move beyond the endless cycle of antiretroviral therapy (ART) for managing HIV? What if instead of just suppressing the virus, there was a treatment that could actually eliminate it?

That’s exactly what researchers are exploring with CAR T-cell therapy, and this isn’t just another theoretical experiment — it’s giving real hope to millions worldwide.

Why CAR T-Cell Therapy Could Change the Game

Right now, over 38 million people around the world live with HIV, relying on ART to keep the virus in check. While ART is effective, it’s a lifelong commitment that comes with side effects, adherence challenges, and no true cure. But what if there were another way?

A new clinical trial, funded by the California Institute for Regenerative Medicine and led by Caring Cross alongside UC Davis Health, is testing a radical new approach: duoCAR T-cell therapy. This treatment isn’t about managing HIV — it’s about potentially eliminating it.

How CAR T-Cell Therapy Works

CAR T-cell therapy is an advanced form of immunotherapy that modifies your immune system to actively seek and destroy HIV-infected cells. Here’s how it works:

  1. T-Cell Collection – Doctors extract T-cells (a type of immune cell) from the patient’s blood.
  2. Genetic Engineering – These T-cells are modified in a lab by adding a Chimeric Antigen Receptor (CAR), a special receptor designed to recognize and attack HIV-infected cells.
  3. Reintroduction into the Body – The enhanced T-cells are then infused back into the patient, where they go to work, hunting down and destroying HIV-infected cells.

Unlike ART, which only suppresses HIV, CAR T-cells might actually eliminate infected cells, potentially reducing or even eliminating the need for daily medication.

Why This Trial Is So Important

CAR T-cell therapy has already revolutionized cancer treatment, successfully treating lymphomas and leukemias where other therapies failed. Now, researchers are applying that same cutting-edge technology to HIV, hoping for a similar breakthrough.

This first-in-human trial is not just a lab experiment — it’s a real-world test. Participants in the trial have maintained an undetectable viral load for at least 12 months using ART. Now, researchers want to see if CAR T-cells can take over where ART leaves off.

Inside the Trial: What’s Happening?

The trial is structured into three groups, each testing a different approach:

  • Cohort 1: Receives a low dose of CAR T-cells. ART is stopped immediately after infusion.
  • Cohort 2: Undergoes mild immune system conditioning with cyclophosphamide before receiving CAR T-cells. ART is stopped afterward.
  • Cohort 3: Receives the same conditioning as Cohort 2 but with a higher dose of CAR T-cells.

Participants are closely monitored for 45 days, with ART restarted if necessary to ensure safety.

Could CAR T-Cells Finally Beat HIV?

The biggest challenge in curing HIV is its ability to hide in “latent reservoirs” within the body, waiting for the right moment to resurface. ART can’t reach these hidden cells, but CAR T-cells can.

Early lab studies and animal models have shown that CAR T-cell therapy can suppress HIV and even eliminate infected cells. Now, the first two participants have received the treatment, and early results are promising — no major side effects, and both individuals are doing well.

What’s Next for CAR T-Cell Therapy?

The trial is still in its early stages, but here’s what to expect next:

  1. Expanding the Study – If the initial results are positive, the trial will scale up to include more participants.
  2. Long-Term Monitoring – Scientists will track how well CAR T-cells control HIV over months and years.
  3. Optimizing the Treatment – Researchers will refine the therapy, making it more efficient and accessible.
  4. Regulatory Approval – If successful, the therapy could move toward FDA approval, making it widely available.

A Future Without HIV?

For decades, the dream of an HIV cure has felt just out of reach. But CAR T-cell therapy could change that. If this treatment works, it could mean a world where people with HIV no longer have to rely on daily ART and live in constant fear of viral rebound.

This isn’t just a scientific breakthrough — it’s a potential turning point in global health. A world without HIV might not be as far away as we once thought.

Source

Connolly, L. (2023, April 19). Clinical trial begins using CAR T cells to potentially cure HIV. UC Davis Health. Retrieved from UC Davis Health.